These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16964379)

  • 1. Regulation of ERK3/MAPK6 expression by BRAF.
    Hoeflich KP; Eby MT; Forrest WF; Gray DC; Tien JY; Stern HM; Murray LJ; Davis DP; Modrusan Z; Seshagiri S
    Int J Oncol; 2006 Oct; 29(4):839-49. PubMed ID: 16964379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
    Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.
    Sumimoto H; Imabayashi F; Iwata T; Kawakami Y
    J Exp Med; 2006 Jul; 203(7):1651-6. PubMed ID: 16801397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells.
    Smith AG; Lim W; Pearen M; Muscat GE; Sturm RA
    Pigment Cell Melanoma Res; 2011 Jun; 24(3):551-63. PubMed ID: 21362156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.
    Kono M; Dunn IS; Durda PJ; Butera D; Rose LB; Haggerty TJ; Benson EM; Kurnick JT
    Mol Cancer Res; 2006 Oct; 4(10):779-92. PubMed ID: 17050671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
    Halilovic E; Solit DB
    Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential mRNA distribution of components of the ERK/MAPK signalling cascade in the adult mouse brain.
    Di Benedetto B; Hitz C; Hölter SM; Kühn R; Vogt Weisenhorn DM; Wurst W
    J Comp Neurol; 2007 Jan; 500(3):542-56. PubMed ID: 17120291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
    Sala E; Mologni L; Truffa S; Gaetano C; Bollag GE; Gambacorti-Passerini C
    Mol Cancer Res; 2008 May; 6(5):751-9. PubMed ID: 18458053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
    Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
    Zipser MC; Eichhoff OM; Widmer DS; Schlegel NC; Schoenewolf NL; Stuart D; Liu W; Gardner H; Smith PD; Nuciforo P; Dummer R; Hoek KS
    Pigment Cell Melanoma Res; 2011 Apr; 24(2):326-33. PubMed ID: 21176117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
    King AJ; Patrick DR; Batorsky RS; Ho ML; Do HT; Zhang SY; Kumar R; Rusnak DW; Takle AK; Wilson DM; Hugger E; Wang L; Karreth F; Lougheed JC; Lee J; Chau D; Stout TJ; May EW; Rominger CM; Schaber MD; Luo L; Lakdawala AS; Adams JL; Contractor RG; Smalley KS; Herlyn M; Morrissey MM; Tuveson DA; Huang PS
    Cancer Res; 2006 Dec; 66(23):11100-5. PubMed ID: 17145850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
    Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
    Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
    Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
    Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.
    Packer LM; East P; Reis-Filho JS; Marais R
    Pigment Cell Melanoma Res; 2009 Dec; 22(6):785-98. PubMed ID: 19682280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.